Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice.

BACKGROUND AND OBJECTIVE To determine outcomes of intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) for treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in routine clinical practice. PATIENTS AND METHODS A retrospective study identified treatment-naïve patients with ME secondary to RVO where treatment with either IVB or IVR was initiated. Retreatment criteria were based on ophthalmic examination and/or spectral-domain optical coherence tomography findings. RESULTS Central RVO/hemi-RVO cohort: At 12 months, change in visual acuity (VA) (IVR: +12.9 letters, IVB +6.9 letters; P = .53), central subfield thickness (CST) (IVR: -144.1 μm, IVB: -153.9 μm; P = .88), and number of injections (IVR: 5.40 injections, IVB: 5.64 injections; P = .70) were not different between groups. Branch RVO cohort: At 12-month follow-up, no differences in change in VA (IVR: +15.2 letters, IVB: +10.6 letters; P = .46), CST (IVR: -23.1 μm, IVB: -91.4 μm; P = .16), or number of injections (IVR: 5.93 injections, IVB: 5.13 injections; P = .15) were noted. CONCLUSION There is no notable difference in outcome between IVR and IVB when treating ME from RVO in routine clinical practice. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:465-472.].

[1]  M. Neudorfer,et al.  Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up) , 2016, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  P. Stavrou,et al.  One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK , 2015, Clinical ophthalmology.

[3]  Bradley T. Smith,et al.  Bevacizumab Versus Ranibizumab in the Treatment of Macular Edema Due to Retinal Vein Occlusion: 6-Month Results of the CRAVE Study. , 2015, Ophthalmic surgery, lasers & imaging retina.

[4]  YangChang-Sue,et al.  Combination therapy with intravitreal bevacizumab and macular grid and scatter laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion. , 2015 .

[5]  T. Das,et al.  A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1 , 2015, British Journal of Ophthalmology.

[6]  T. Wong,et al.  Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. , 2014, American journal of ophthalmology.

[7]  T. Peto,et al.  A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. , 2012, Archives of ophthalmology.

[8]  M. Michaelis,et al.  Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion , 2012, Acta ophthalmologica.

[9]  G. Yancopoulos,et al.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.

[10]  J. Seland,et al.  Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. , 2010, American journal of ophthalmology.

[11]  P. Rosenfeld,et al.  NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTS , 2010, Retina.

[12]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[13]  P. Campochiaro,et al.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[14]  Y. Hata,et al.  Comprehensive Analysis of Inflammatory Immune Mediators in Vitreoretinal Diseases , 2009, PloS one.

[15]  Ingrid U Scott,et al.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. , 2009, Archives of ophthalmology.

[16]  A. Barone,et al.  BEVACIZUMAB COMPARED WITH MACULAR LASER GRID PHOTOCOAGULATION FOR CYSTOID MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION , 2009, Retina.

[17]  L. Damico,et al.  DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[18]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[19]  P. Campochiaro,et al.  Cellular mechanisms of blood-retinal barrier dysfunction in macular edema , 2004, Documenta Ophthalmologica.

[20]  I. Cree,et al.  Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. , 2002, Archives of ophthalmology.

[21]  David J. Wilson,et al.  Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. , 1995, Ophthalmology.